Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | CAR-T therapy versus autoSCT in DLBCL

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, compares the use of CAR-T therapy versus autologous stem cell transplantation (autoSCT) in diffuse large B-cell lymphoma (DLBCL). Prof. Kröger first describes evidence that CAR-T therapy may be more likely to benefit patients with relapsed/refractory (R/R) disease, and then goes on to explain that autoSCT may still play a role in patients with early relapse or who are chemosensitive to salvage therapy. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.